IL2RA and cancer: Therefore, we believe that the application of anti-IL-2Rα MAbs during standard chemotherapy-induced lymphopenia in patients with cancer will selectively ablate or inactivate TRegs while permitting immune responses induced by anti-tumor immunotherapy.